Background and aims The association between body mass index (BMI) and clinical
outcomes of patients with non-valvular atrial fibrillation (NVAF) taking oral anticoagulants …

We present the case of a 80-year-old man with atrial fibrillation, morbid obesity (weight 123
kg, height 167 cm, BMI 44.1), high clearance of creatinine and pharmacological polytherapy …

Background Frailty and comorbidity influence the therapeutic approach in everyday clinical
practice. The DOACs genericization opens a reflection on their differences from a …

Background The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI)
are well known indicators for adverse outcomes in various diseases, but there is no …

Patients at extremes of body weight are underrepresented in randomized controlled trials of
direct-acting oral anticoagulants (DOACs). Therefore, their optimal anticoagulant treatment …

Background and Purpose: Edoxaban exposure varies across different ethnicities. The
purpose of our study was to examine the risk factors associated with high or low edoxaban …

Introduction Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for
stroke prevention in patients with atrial fibrillation (AF). Since NOACs are predominantly …

We present the case of a 45-year-old man with atrial fibrillation and morbid obesity (weight
128 kg, height 168 cm, BMI 45.4) who was switched from Warfarin 5 mg once daily to …

Background Uncertainty remains regarding the association between body mass index (BMI)
and the risk of bleeding in patients with non-valvular atrial fibrillation (NVAF). We aimed to …

Background: In randomized trials, cangrelor reduced periprocedural ischemic events related
to percutaneous coronary intervention without increasing GUSTO severe bleeding …